GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Henlius Biotech 2696.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

49.78

+1.55%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥7.78bn

FY2017FY2025

Net income

CN¥939.8m

FY2017FY2025

Free cash flow

CN¥1.00bn

FY2017FY2025

Shareholders' equity

CN¥4.62bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥7.78bnCN¥5.72bnCN¥5.39bnCN¥3.21bnCN¥1.96bnCN¥587.6mCN¥90.9mCN¥7.4mCN¥33.9m
Gross profitCN¥5.81bnCN¥4.18bnCN¥3.92bnCN¥2.37bnCN¥1.35bnCN¥405.5mCN¥19.1mCN¥2.0mCN¥18.9m
Research and developmentCN¥1.77bnCN¥1.04bnCN¥1.12bnCN¥1.39bnCN¥1.19bnCN¥894.1mCN¥607.8mCN¥365.4mCN¥257.1m
Operating incomeCN¥953.2mCN¥939.1mCN¥631.7m−CN¥591.8m−CN¥1.02bn−CN¥957.2m−CN¥842.6m−CN¥447.5m−CN¥324.8m
Net incomeCN¥939.8mCN¥820.5mCN¥546.0m−CN¥695.3m−CN¥1.15bn−CN¥993.5m−CN¥875.5m−CN¥493.7m−CN¥270.6m
Diluted earnings per share1.711.511.00-1.28-2.13-1.86-1.61-1.04-0.50

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥14.43bnCN¥12.36bnCN¥11.55bnCN¥10.41bnCN¥8.37bnCN¥6.44bnCN¥5.90bnCN¥3.09bnCN¥1.48bn
Cash and short-term investmentsCN¥901.1mCN¥901.6mCN¥1.18bnCN¥793.8mCN¥865.9mCN¥1.11bnCN¥2.33bnCN¥959.0mCN¥58.5m
Total liabilitiesCN¥9.80bnCN¥8.85bnCN¥8.99bnCN¥8.50bnCN¥5.69bnCN¥3.24bnCN¥1.90bnCN¥1.29bnCN¥1.56bn
DebtCN¥4.20bnCN¥3.65bnCN¥4.09bnCN¥3.68bnCN¥2.62bnCN¥1.83bnCN¥609.4mCN¥528.0mCN¥758.4m
Shareholders' equityCN¥4.62bnCN¥3.52bnCN¥2.56bnCN¥1.91bnCN¥2.68bnCN¥3.20bnCN¥4.00bnCN¥1.80bn−CN¥80.1m
Shares outstanding548m543m544m543m540m534m543m474m539m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥1.36bnCN¥1.24bnCN¥1.22bnCN¥1.15bnCN¥105.4m−CN¥609.6m−CN¥443.1m−CN¥52.2m−CN¥134.3m
Capital spending−CN¥353.8m−CN¥837.2m−CN¥1.18bn−CN¥1.59bn−CN¥1.32bn−CN¥1.51bn−CN¥1.13bn−CN¥735.4m−CN¥471.7m
Free cash flowCN¥1.00bnCN¥404.7mCN¥42.5m−CN¥447.5m−CN¥1.21bn−CN¥2.12bn−CN¥1.58bn−CN¥787.6m−CN¥606.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.09bnCN¥2.09bnCN¥2.24bnCN¥2.24bnCN¥1.64bnCN¥1.64bnCN¥1.49bnCN¥1.74bn
Gross profitCN¥1.61bnCN¥1.61bnCN¥1.62bnCN¥1.62bnCN¥1.28bnCN¥1.28bnCN¥1.10bnCN¥1.28bn
Operating incomeCN¥297.1mCN¥297.1mCN¥230.1mCN¥221.4mCN¥250.8mCN¥250.8mCN¥209.2mCN¥244.0m
Net incomeCN¥251.0mCN¥251.0mCN¥254.8mCN¥254.8mCN¥227.5mCN¥227.5mCN¥217.1mCN¥253.2m
Diluted earnings per share0.460.460.460.460.410.410.400.47
Cash from operations——CN¥311.0mCN¥311.0mCN¥449.0mCN¥449.0mCN¥495.0mCN¥577.0m
Capital spending——−CN¥80.0m−CN¥80.0m−CN¥101.0m−CN¥101.0m−CN¥30.0m−CN¥35.0m
Free cash flow——CN¥231.0mCN¥231.0mCN¥348.0mCN¥348.0mCN¥465.0mCN¥542.0m
Total assetsCN¥15.28bnCN¥15.28bnCN¥14.42bnCN¥14.42bnCN¥13.47bnCN¥13.47bnCN¥10.60bnCN¥12.36bn
Cash and short-term investmentsCN¥1.12bnCN¥1.12bnCN¥900.8mCN¥983.6mCN¥1.13bnCN¥1.13bnCN¥773.0mCN¥949.2m
DebtCN¥2.64bnCN¥2.64bnCN¥4.20bnCN¥2.62bnCN¥4.37bnCN¥3.10bnCN¥3.65bnCN¥3.06bn
Shareholders' equityCN¥5.29bnCN¥5.29bnCN¥4.62bnCN¥4.62bnCN¥3.98bnCN¥3.98bnCN¥3.01bnCN¥3.52bn

Financial ratios

Data as of 18 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin74.8%73.1%72.6%73.7%68.9%69.0%
Operating margin12.3%16.4%11.7%-18.4%-52.0%-162.9%
Net margin12.1%14.3%10.1%-21.6%-58.5%-169.1%
Return on equity20.3%27.2%24.9%-42.5%-42.8%-31.1%
Return on assets6.5%7.7%5.5%-7.8%-13.7%-15.4%
Free cash flow yield4.5%6.4%6.3%7.2%3.8%2.8%
Revenue growth16.5%6.1%67.8%91.1%186.3%546.2%
Earnings growth-1.8%50.3%-178.5%-29.3%-1.0%13.5%
Current ratio0.71x0.50x0.53x0.44x0.56x0.96x
Debt to equity0.91x1.16x1.78x2.14x1.14x0.57x
Equity ratio32.0%28.4%22.1%18.3%32.0%49.7%
Interest coverage8.18x7.64x5.71x-5.60x-10.31x-21.90x
R&D as a share of sales22.7%18.1%20.7%43.4%60.9%152.2%
Buybacks as a share of market value-0.9%0.0%-0.2%-0.5%-1.0%1.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue34.2%67.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin74.1%73.7%73.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings28.813.612.0-8.7-9.0-21.8-21.9
Price to sales3.51.91.21.95.336.8210.5

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.